<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The only treatment of patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> is thrombolytic therapy, which benefits only a fraction of <z:hpo ids='HP_0001297'>stroke</z:hpo> patients </plain></SENT>
<SENT sid="1" pm="."><plain>Both human and experimental studies indicate that <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> involves secondary <z:mp ids='MP_0001845'>inflammation</z:mp> that significantly contributes to the outcome after ischemic insult </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="1" ids="50694">Minocycline</z:chebi> is a semisynthetic second-generation <z:chebi fb="9" ids="27902">tetracycline</z:chebi> that exerts antiinflammatory effects that are completely separate from its antimicrobial action </plain></SENT>
<SENT sid="3" pm="."><plain>Because <z:chebi fb="9" ids="27902">tetracycline</z:chebi> treatment is clinically well tolerated, we investigated whether <z:chebi fb="1" ids="50694">minocycline</z:chebi> protects against focal <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> with a wide therapeutic window </plain></SENT>
<SENT sid="4" pm="."><plain>Using a rat model of transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, we show that daily treatment with <z:chebi fb="1" ids="50694">minocycline</z:chebi> reduces cortical infarction volume by 76 +/- 22% when the treatment is started 12 h before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and by 63 +/- 35% when started even 4 h after the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The treatment inhibits morphological activation of microglia in the area adjacent to the infarction, inhibits induction of IL-1beta-converting enzyme, and reduces cyclooxygenase-2 expression and <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> E(2) production </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="1" ids="50694">Minocycline</z:chebi> had no effect on <z:mp ids='MP_0003354'>astrogliosis</z:mp> or spreading <z:hpo ids='HP_0000716'>depression</z:hpo>, a wave of ionic transients thought to contribute to enlargement of cortical infarction </plain></SENT>
<SENT sid="7" pm="."><plain>Treatment with <z:chebi fb="1" ids="50694">minocycline</z:chebi> may act directly on brain cells, because cultured primary neurons were also salvaged from <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> toxicity </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="1" ids="50694">Minocycline</z:chebi> may represent a prototype of an antiinflammatory compound that provides protection against <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> and has a clinically relevant therapeutic window </plain></SENT>
</text></document>